• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cough - Pipeline Review, H2 2012 Product Image

Cough - Pipeline Review, H2 2012

  • ID: 2245177
  • September 2012
  • 69 pages
  • Global Markets Direct

Cough – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cough - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cough, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cough. Cough - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cough.
- A review of the Cough products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Cough Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Cough 9
Cough Therapeutics under Development by Companies 11
Cough Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Cough Therapeutics – Products under Development by Companies 18
Cough Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Cough Therapeutics Development 20
GlaxoSmithKline plc 20
Merck & Co., Inc. 21
Novartis Vaccines and Diagnostics, Inc. 22
OPKO Health, Inc. 23
Collegium Pharmaceutical, Inc. 24
Ahn-Gook Pharmaceutical Co., Ltd. 25
PhytoHealth Corporation 26
Verona Pharma Plc 27
Lipocine Inc. 28
Afferent Pharmaceuticals, Inc. 29
AUS Bio Limited 30
Cough – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
rolapitant hydrochloride - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SB-705498 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SCH-900978 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VRP-700 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AF-219 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PHN-081 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
azithromycin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AG PPC-709 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AG-1321001SY - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AG NDT-802 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
V501 + Menactra + Adacel - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
budesonide - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BPZE-1 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
COL-112 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
COL-131 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
FP01 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
prednisone - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
GSK-2339345 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Acellular Pertussis Vaccine + Tetanus-Diphtheria Booster Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MD-990 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cough Therapeutics – Drug Profile Updates 58
Cough Therapeutics – Discontinued Products 62
Cough Therapeutics - Dormant Products 63
Cough – Product Development Milestones 64
Featured News & Press Releases 64
Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency 64
Apr 11, 2012: Cerecor Announces Clearance Of IND For FP01 65
Sep 07, 2011: Verona Pharma Announces Results From Clinical Trial Of VRP700 65
Oct 27, 2010: Verona Pharma Initiates Clinical Trial Of VRP700 For Chronic Cough 66
Jun 28, 2010: Verona Pharma Seeks Regulatory Approval For Cough Trial 66
Feb 05, 2009: PhytoHealth Completes Patient Enrollment In Phase II Clinical Trial Of PHN081 (PDC-748), An Antitussive New Drug Candidate 66
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables
Number of Products Under Development for Cough, H2 2012 9
Products under Development for Cough – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
GlaxoSmithKline plc, H2 2012 20
Merck & Co., Inc., H2 2012 21
Novartis Vaccines and Diagnostics, Inc., H2 2012 22
OPKO Health, Inc., H2 2012 23
Collegium Pharmaceutical, Inc., H2 2012 24
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 25
PhytoHealth Corporation, H2 2012 26
Verona Pharma Plc, H2 2012 27
Lipocine Inc., H2 2012 28
Afferent Pharmaceuticals, Inc., H2 2012 29
AUS Bio Limited, H2 2012 30
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 36
Cough Therapeutics – Drug Profile Updates 58
Cough Therapeutics – Discontinued Products 62
Cough Therapeutics – Dormant Products 63

List of Figures
Number of Products under Development for Cough, H2 2012 9
Products under Development for Cough – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Route of Administration, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Molecule Type, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 36

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos